{"entity":{"id":"nct06640361","kind":"trial","name":"A Study of Olverembatinib in SDH-deficient GIST.","aka":["POLARIS-3"],"tldr":"A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.","summary":"A Study of Olverembatinib in SDH-deficient GIST. is a phase 3 interventional study registered as NCT06640361 by Ascentage Pharma Group Inc., with 40 participants planned, started 2024-11-11. Conditions listed: GIST. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06640361","url":"https://clinicaltrials.gov/study/NCT06640361"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gist"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["olverembatinib"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06640361","phase":"3","setting":"A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)","sponsor":"Ascentage Pharma Group Inc.","started":"2024-11-11","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06640361/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}